In the original publication [1], the authors wish to revise the arrow of the epithelial–mesenchymal transition (EMT) in the schematic representation of the mechanism of suppressing cancer metastasis in Figure 1, which was overlooked in the final proofreading.
In Figure 1, in the schematic representation of the mechanism of suppressing cancer metastasis by suppressing the epithelial–mesenchymal transition (EMT), E-calmodulin should be upregulated instead of downregulated. Therefore, an upward arrow should be used instead of a downward arrow.
This is the corrected figure:
Figure 1.
Microbiome affects cancer metastasis through epithelial–mesenchymal transition (EMT). Fn, Fusobacterium nucleatum; ADH1B, alcohol dehydrogenase 1B; TGFBR2, transforming growth factor β receptor 2; IPA, indolepropionic acid. Figure created with BioRender.com on 14 January 2023.
Figure 1.
Microbiome affects cancer metastasis through epithelial–mesenchymal transition (EMT). Fn, Fusobacterium nucleatum; ADH1B, alcohol dehydrogenase 1B; TGFBR2, transforming growth factor β receptor 2; IPA, indolepropionic acid. Figure created with BioRender.com on 14 January 2023.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.
Reference
- Liu, J.; Luo, F.; Wen, L.; Zhao, Z.; Sun, H. Current Understanding of Microbiomes in Cancer Metastasis. Cancers 2023, 15, 1893. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).